Skip to main content

Diabetes

  • Diabetes diagnoses spiking worldwide

    Diabetes has become a worldwide epidemic. According to data recently published by the Brussels-based International Diabetes Federation, by 2040 more than 642 million people worldwide will suffer from diabetes, up from 415 million in 2015, the last year for which the organization has statistics. In North America, this figure is expected to jump from the current 30 million cases to around 41 million.

    (To view the full Category Review, click here.)

  • Drug stores to play bigger diabetes role

    CVS Health senior educator Kristene Diggins and others involved in the fight against diabetes said they expect drug stores and retail clinics to play a bigger role in coming years.

    (To view the full Category Review, click here.)

  • Ascensia, Glooko improve diabetes management through new partnership

  • J&J exploring strategic options for LifeScan unit

    NEW BRUNSWICK, N.J.  — Johnson and Johnson on Tuesday announced it will be evaluating "potential strategic options" for its LifeScan diabetes business, as well as other J&J diabetes banners including Animas Corp. and Calibra Medical.

    The news was announced in conjunction with the company's fourth quarter earnings call, and is part of the company's ongoing portfolio management.

  • ShopRite offers free health-and-wellness offerings

    KEASBEY, N.J. — ShopRite is introducing a variety of health and wellness offerings for its supermarket customers throughout 2017.

    These services include:

    Free Eat Well, Be Happy Weight Management Classes — This six-week class teaches portion control, label reading, better-for-you cooking techniques and lifestyle maintenance.

    Free Diabetes Classes — Runs throughout the year and features one-hour long sessions focusing on several aspects of diabetes. Held in partnership with ShopRite Pharmacy.

  • White paper: Diabetes diagnoses doubles across pediatric population

    NEW YORK  — Private health insurance claim lines with a type 2 diabetes diagnosis more than doubled in the pediatric population (ages 0 to 22 years) from 2011 to 2015, increasing 109%, according to data from FAIR Health, a national, independent, nonprofit organization dedicated to bringing transparency to healthcare costs and health insurance information.

  • Dexcom Glucose Monitoring System classified as ‘therapeutic’ by CMS

    SAN DIEGO — The U.S. Department of Health and Human Services Centers for Medicaid and Medicare Services classified Dexcom’s G5 Mobile Continuous Glucose Monitoring system as “therapeutic,” meaning treatment decisions can be made using the device.

    According to Dexcom, it is the only continuous glucose monitoring system that falls under this designation.

  • Sanofi announces U.S. availability of Soliqua 100/33

    PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     
X
This ad will auto-close in 10 seconds